Actively Recruiting
PROTECT-Africa Validating Biomarker Tests to Improve Preeclampsia Care in African Pregnancies
Led by Africa Clinical Research Network (ACRN) · Updated on 2026-09-09
1106
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Preeclampsia is a serious condition of high blood pressure during pregnancy, causing significant health risks for mothers and babies in Africa. This research is studying how well two blood proteins, sFlt-1 and PlGF, can predict severe preeclampsia in African women. The study aims to find the best ratio thresholds for prediction and to test rapid, clinic-based tests that measure these proteins quickly without needing large labs. The study involves about 1,106 pregnant women between 23 and 37 weeks with suspected preeclampsia from hospitals in Zimbabwe, Rwanda, and Tanzania. It is divided into two parts Part A determines and confirms the best sFlt-1PlGF ratio thresholds using a laboratory test, while Part B evaluates rapid tests against these thresholds. Blood and urine samples will be collected, and some stored samples may be tested later with new platforms. Participants will attend their usual pregnancy visits plus additional study visits at 1, 2, and 4 weeks after enrollment, at delivery, and about 4 weeks postpartum. At these visits, health information and samples are collected, but test results are not shared with participants or their care teams and do not affect treatment. The study also analyzes costs and potential savings, aiming to improve early detection of dangerous preeclampsia in African clinics.
CONDITIONS
Brief Title
PROTECT-Africa: Biomarker Validation for Preeclampsia Triage
Research Team
T
Tariro Makadzange
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here